Author name: Leonardo Arias

The New York-based provider said it’s cutting less than 2% of staff as it contends with rising expenses.

In letters to Eli Lilly and Novo Nordisk, the FDA accused the companies of downplaying the risks of their GLP-1 weight loss drugs during a prime time special with Oprah Winfrey.

The continuing resolution would fund the government, and preserve the flexibilities, through Nov. 21. But the bill makes no mention of extending more generous financial assistance for people who buy plans on the exchanges.

The continuing resolution would fund the government, and preserve the flexibilities, through Nov. 21. But the bill makes no mention of extending more generous financial assistance for people who buy plans on the exchanges.

A complex state vs. federal regulatory scheme allows drug compounders to advertise drugs without disclosing risks like a pharma company must do. Experts say it’s time for the FDA to crack down.

America’s primary care chassis is crumbling. How Medicare pays physicians is partially to blame. But expanding value-based payment arrangements could be the answer, experts say.

The over-representation of males and Hispanic patients in Eli Lilly’s Phase III ATTAIN-1 study could explain why orforglipron “underperformed” expectations in a previous readout, according to analysts at BMO Capital Markets.

This manufacturing site in Richmond, Virginia, is the first of four projects that Eli Lilly plans to reveal this year as part of a $27 billion U.S. investment announced earlier this year.

  En los últimos años, las ciudades se han visto obligadas a repensar la forma en que gestionan el creciente flujo de mercancías derivado del auge del comercio electrónico. La entrega a domicilio tradicional, con múltiples furgonetas circulando por las call …

The White House is clamping down on pharma’s ability to buy new molecules from Chinese biotechs; Sanofi, Merck and others abandon the U.K. after the introduction of a sizeable levy; Novo CEO Maziar Mike Doustdar lays off 9,000 while the company presents new data at EASD; Capsida loses a patient in a gene therapy trial;